Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 46

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 46
---
 study
with more than 100 subjects. In 2015, Chromocell Holdings signed an agreement with Astellas Pharma Inc. (“Astellas”)
for the joint development and commercialization of CC8464. Astellas terminated such agreement in 2018 and returned all rights,
including all intellectual property rights on CC8464, to Chromocell Holdings.

As
both the flavors and the therapeutics businesses grew and increasingly required different expertise, capital and business concepts,
Chromocell Holdings made the strategic decision to separate the two businesses.

Channel
Therapeutics Corporation was incorporated in Delaware on March 19, 2021. On November 18, 2024 (“Reincorporation Merger Effective
Date”), Chromocell Therapeutics Corporation, a Delaware corporation (the “Predecessor”), merged with and into
its wholly-owned subsidiary, Channel Therapeutics Corporation, a Nevada corporation (the “Reincorporation Merger”),
pursuant to an agreement and plan of merger, dated as of November 18, 2024 (the “Reincorporation Merger Agreement”).
All information disclosed in this Form 10-K for periods prior to the Reincorporation Merger Effective Date relates to the Predecessor,
and all information disclosed in this Form 10-K for periods after the Reincorporation Merger Effective Date relates to Channel
Therapeutics Corporation, a Nevada corporation.

Our
principal executive offices are located at 4400 Route 9 South, Suite 1000, Freehold, NJ 07728, and our telephone number is (732)
514-2636. Our website is www.channeltherapeutics.com. Information contained on, or that can be accessed through, our website
is not incorporated by reference into this Report, and you should not consider information on our website to be part of this Report.

We
make available free of charge under the “Investors” section of our website all of our filings with the Securities
and Exchange Commission (the “SEC”), including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current
reports on Form 8-K, proxy statements and amendments to such documents, each of which is provided on our website as soon as reasonably
practicable after we electronically file or furnish, as applicable, the information with the SEC.  

26 

Implications
of Being an Emerging Growth and Smaller Reporting Company

We
qualify as an “emerging growth